| Literature DB >> 18188936 |
John J Alexander1, William W Hauswirth.
Abstract
Recombinant adeno-associated viral vectors have slowly been moving to the forefront of gene therapy experiments. Given the non-pathogenic nature, low immunogenicity, ease of delivery, persistence, and targeting possibilities of rAAV, it is poised to become a major player in retinal gene therapy.Mesh：
Year: 2008 PMID： 18188936 DOI： 10.1007/978-0-387-74904-4_13
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622